 CAMBRIDGE, Mass., Nov. 03, 2022 GLOBE NEWSWIRE -- Immuneering Corporation Nasdaq: IMRX, a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today announced that management will participate in three November investor conferences to share commentary around the Companys pipeline, platform, and business strategy. Presenting will be Ben Zeskind, Ph.D., Co-Founder, and Chief Executive Officer and Brett Hall, Ph.D., Chief Scientific Officer. 